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Aim: To evaluate CFI'R gene involvement in47 Portuguese patients with congenital 
absence of the vas deferens (CAVD). 
Methods: Patients were first screened for the 31 most frequent CF mutations using 
a commercial kit. The whole CFI'R gene coding region was studied by Denaturing 
Gradient Gel Electrophoresis (DGGE) and denaturing High Performance Liquid 
Chromatography (dHPLC). CFI'R gene reaTrangements were searched by semi 
quantitative fluorescent multiplex PCR (QFM PCR). Poly T variants of intron 8 
(1342 6(T)5 9) were studied by fluorescent PCR and fragment analysis using an 
automated DNA analyser. Poly TG at 1342 12(TG)9 13 was analysed by DGGE for 
the patients cart3~ing the 5T variant. 
Results: Initial screening identified 28 CF mutations ha 24 patients (51.1%). 
DGGE/dHPLC analysis detected 23 further mutations, of which 3 were novel 
missense. QFM PCR detected a large deletion in one patient and confirmed the 
homozygous status for a mutation ha two others. The 5T variant of intron 8 was 
found ha 27 alleles (28.7% of total alleles). These steps increased the number of 
cases with at least one CFTR mutation to 38 (80.8%): 33 (70.2%) had two mutations 
and 5 (10.6%) had one. Nine cases (19.1%) remained with no detected mutation. 
The compound heterozygosity of the 5T variant and a CF or CFI'R mutation 
accounted for 15/33 (45.4%) of the total known genotypes. 
Conclusions: We first describe the type and frequency of CFTR mutations ha 
Portuguese CAVD patients, showing that the most common genetic ause is due to 
combination between the 5T allele with CFTR mutations. 
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Contribution of the pancreatic secretory kypsin inhibitor gene 
(SPINK1) to the etiology of CFTR-related recurrent pancreafitis 
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The aim was to evaluate the hypothesis that the CFTR may interact with PRSS1 
and/or SPINK1 genes to predispose to recurrent pancreatitis (RP). 
Methods: 28 patients with RP were studied. Infectious, metabolic and biliary causes 
were excluded. Sweat chloride and fecal pancreatic elastase determinations were 
performed CFTR, PRSS1 and SPINK1 genes were screened applying Denaturing 
Gradient Gel Electrophoresis (DGDE). 
Results: 22 patients had CF and excerine pancreatic sufficiency while 6 patients had 
normal sweat chloride and fecal elastase concentrations. 
CFI'R gene 18128 carried only one mutation [R1070Q, G576A, 2789+5G>A, 
F1052V, E822X, F508del, CFTRdeI12, 3(21KB)] and 4/28 carried two mutations 
(F508del/R334W, 444delA/R334W, 1571delGtNV1282X). 
PRSSI gene Polymorpbisms D162D (486CTT) and N246N (738C/T) were found in 
8 and 5 patients, respectively. 
SPINKI gene The promoter polymorpbism 253T>C was found in 3 individuals; 
213 were also cattier s of mutation R1070Q and 113 also carried G576A. 
Conclusion: These preliminary results suggest that the promoter polymotpbism 
253T>C of the SPINK1 gene, when found in canciers of CF IR  mutations, may 
present high risk for recurrent pancreatitis. 
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Identification of a new CFTR complex allele 
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The V754M variant is considered as a CF mutation, being first described ha 1996 in 
a CF patient. However, there are several lines of evidence against its strong 
deleterious effect: the conservative nature of the Val>Met substitution; the presence 
of a Met residue in place of Val in some species; results of functional studies which 
suggest that the V754 residue does not belong to the functional R domain; finally, 
the identification of a complex deletion removing exons 3 10 and 14~16 in cis of 
V754M ha a CF patient. 
Aims: We thus aimed to make an inventory of French patients caTrying V754M, 
look for CFTRdele3 10,14~16 and determine the phenotypes associated with 
V754M ha isolation and in the complex allele context. 
Methods: Four patients (CF: n=3; idiopathic chronic pancreatitis: n=l)  and five 
healthy partners of patients or of carriers, who are heterozygous for V754M, were 
analysed for the presence of the complex deletion by semi quantitative multiplex 
fluorescent PCR. All the CFTR gene coding regions were also analysed to look for 
other possible anomalies. Analysis of five intr agenic micr osatellites was performed 
to determine the associated haplotypes. 
Results: Only the three CF patients caTried the complex deletion, which is 
associated with the same haplotype. No other mutation was detected in the 
individuals tested. 
Conclusion: We suggest looking for a possible deletion whenever V754M is 
detected and considering it as a neutral polymorphism when found in isolation. 
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Different CFTR genotypes induce dissimilar expression patterns in 
CF putative gene modifiers 
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Cystic fibrosis (CF; #219700) is a disorder caused by mutations in the CFFR gene, 
characterized by a wide variability of clinical expressions, modulated by "modifier 
genes". 
We built a home made cDNA micr oancay to characterize differently expressed genes 
in two CF cell lines with different genotype (OaFil F508del/F508del; CuFi3 
F508del/R553X), to identify genes and pathways that interact with or compensate 
for the mutated CFrR  to mant ain physiological functions. 
Between the 150 genes analysed, 36 emerged ifferentially expressed in CYRil , 
while 40 in Oafl3. 
We observed difference in change in the infiammatory response, in protein 
degradation pathways, in molecular chaperones, in channels and in CFTR 
interacting proteins. 
Some of those genes sbared the same expression pattern in the two cell line, like 
iperexpression of S1COA8 and S1COA9 (according to CF IR  knock out mice), 
ipoexpression of SMAD3 and SMAD4 of the inflammatory response, and the 
iperexpression of sodium channel ENaC. Others had different expression pattern, 
like RNA encoding for AP (Adaptor Protein complex) of the degradation pathway. 
Expression levels of subunits AP1M2 and AP3B1 are increased in Cnfil(10 fold), 
while their are decreased in Cufl3 (2 fold). Otherwise, AP1M1 is 1.6 fold increased 
in Cnfil and 1.6 fold decreased in Ckffi3, whileAP1S1 is ovetrepresented (1.7 fold) 
only ha Cufll. 
Data has been confirmed by Real Time PCR. 
These data suggest that different CFrR mutations cause different genomic 
response, and help us to understand which are the possible modifier genes that have 
to be considered in future. 
